Roche is wasting no time in getting out its checkbook in 2025, signing a new biobucks-heavy pact that aims to add another new antibody-drug conjugate (ADC) to its pipeline. Roche, which put billions ...

LONDON, Sept 22 (Reuters) - Swiss drugmaker Roche (ROG.S), opens new tab signalled its ambition to join Eli Lilly and Novo Nordisk at the top of the booming weight-loss market on Monday, as it ...

Roche and Zealand Pharma in March struck a deal worth up to $5.3 billion to co-develop and co-commercialize amylin analog petrelintide as a potentially "next generation" weight loss drug. Executives ...

Discover how early CMC, process optimization, and formulation strategy drive scalable, commercially viable drugs.

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Roche will advance an experimental Parkinson’s disease ...

Designing an efficient platform is crucial for any industrial process. This design process is known as process development, and it has become increasingly important in the pharmaceutical industry at ...

Following the apparent elimination of a late-stage gene therapy study last week, Swiss drug juggernaut Roche has confirmed that it’s axing a hemophilia candidate inherited in its 2019 buyout of Spark ...

Roche targets liver disease treatments with acquisition Deal includes $14.50 a share, potential milestone payments up to $6.00 a share Roche flags potential to treat obesity-related conditions The ...

Roche received a major boost Tuesday when the company announced its experimental oral medication giredestrant successfully reduced the risk of breast cancer returning after surgery, delivering a much ...